PART I Overview We are a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies, including antibody-drug conjugates (ADCs). An ADC consists of a monoclonal antibody conjugated to a cytotoxic drug via a chemical linker. We focus on advancing therapies that leverage our core strengths in understanding biological pathway...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001104659-26-024137 | EDGAR | 79K words |
| 2025-03-06 | 2024-12-31 | 0001558370-25-002402 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001558370-24-003672 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001558370-23-002698 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001558370-22-002824 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001558370-21-002384 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001558370-20-002566 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001104659-25-107036 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010782 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001558370-25-006111 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014869 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001558370-24-010605 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001558370-24-006551 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017429 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001558370-23-013250 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008131 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016275 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012232 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007439 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001104659-26-024121 | EDGAR | 2K words |
| 2026-01-23 | 0001104659-26-006021 | EDGAR | — |
| 2025-12-19 | 0001104659-25-123305 | EDGAR | — |
| 2025-11-17 | 0001104659-25-112975 | EDGAR | — |
| 2025-11-05 | 0001104659-25-107008 | EDGAR | — |
| 2025-08-25 | 0001558370-25-011752 | EDGAR | — |
| 2025-08-07 | 0001558370-25-010774 | EDGAR | — |
| 2025-07-14 | 0001558370-25-009214 | EDGAR | — |
| 2025-07-10 | 0001558370-25-009163 | EDGAR | — |
| 2025-06-23 | 0001558370-25-008789 | EDGAR | — |
107 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001661059 |
| Ticker | NXTC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nextcure.com |
| Listed | 2019-05-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report